Document is current
Any future updates will be listed below
-
Authors
Noli, B.
Muqaku, B.
Gouda, M.
Manai, AL.
Nagl, M.
Anderl-Straub, S.
Werner, L.
Otto, M.
Teunissen, C. E.
Oeckl, P.
Cocco, C. https://orcid.org/0000-0003-3915-208X
-
Funding
Funding for this research was provided by:
Università degli Studi di Cagliari
- License Information
-
More Information
Article History
Received: 25 July 2025
Revised: 1 October 2025
Accepted: 4 October 2025
First Online: 4 November 2025
Declarations
:
: PO received research support from the Cure Alzheimer Fund, ALS Association (24-SGP-691, 23-PPG-674–2), ALS Finding a Cure, the Charcot Foundation, the DZNE Innovation-to-Application program, consulting fees from LifeArc and Fundamental Pharma and travel support from Biogen. CET has reseach contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics,Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vivoryon. She is editor in chief of Alzheimer Research and Therapy, and serves on editorial boards of Medidact Neurologie/Springer, and Neurology: Neuroimmunology & Neuroinflammation. M.O. received research support from the German Federal Ministry of Education and Research (projects: FTLDc 01GI1007A), the EU Moodmarker programme (01EW2008), the ALS Association, the foundation of the state Baden-Württemberg (D.3830), Boehringer Ingelheim Ulm University BioCenter (D.5009), and the Thierry Latran Foundation and EU‐MIRIADE and the Roux-programme of the Martin Luther University Halle (Saale); M.O. received consulting fees from Biogen, Axon, Roche, and Grifols; and participates on the Biogen ATLAS trial board.
